. KSHV-MCD is characterized by inflammatory symptoms, progressive fatigue, and weight loss. Symptomatic patients generally have elevated C-reactive protein (CRP) and KSHV viral load, and often have anemia, thrombocytopenia, hypoalbuminemia, hyponatremia, and elevated gammaglobulin [2] [3] [4] [5] [6] [7] [8] [9] . Computerized tomography (CT) typically demonstrates diffuse adenopathy and splenomegaly. Diagnosis requires pathologic confirmation.
KSHV-infected plasmablasts often express KSHV-encoded viral interleukin-6
(vIL-6) and other lytic genes. KSHV is also the etiologic agent of Kaposi sarcoma (KS) 10 and primary effusion lymphoma (PEL) 11, 12 . Patients with KSHV-MCD commonly have concurrent KS, often involving lymph nodes, and are at risk of developing KS, PEL and large cell-lymphoma arising in KSHV-MCD [13] [14] [15] [16] . KSHV-MCD often has a waxing and waning course. Untreated, it is usually lethal within 2 to 3 years 1, 7 . Patients can develop severe sepsis-like manifestations associated with elevated human interleukin (IL)-6, vIL-6, and IL-10 17 and/or hemophagocytic syndrome 18, 19 . Such disease manifestations require urgent treatment. Additionally, managing patients with more than one KSHVassociated malignancy requires accurate diagnoses and personalized treatment.
Unlike idiopathic MCD [20] [21] [22] [23] , there is no FDA-approved therapy for KSHV-MCD. Disease control has been reported with chemotherapeutic agents used for Rituximab was evaluated in two phase 2 studies. In the CastlemaB Study, 24 HIV-infected patients with chemotherapy-dependent KSHV-MCD received rituximab 375 mg/m 2 weekly for four weeks 34 . 92% had sustained resolution of MCD symptoms 60 days after initiation of rituximab. At one year, 71% were alive and disease-free 34 . In a second study, 21 patients with symptomatic KSHV-MCD were treated with rituximab 375 mg/m 2 weekly for four weeks 35 . 95% had resolution of symptoms and significant decreases in KSHV viral load and CRP.
79% were relapse-free at 2 years 35 . However, in these rituximab studies,
worsening KS was observed in 35-67% of patients with baseline KS 34, 35 , suggesting that additional approaches are required for the substantial subset of
For personal use only. on July 10, 2017. by guest www.bloodjournal.org From 7 KSHV-MCD patients with concurrent KS. The pathophysiology of KS progression in the setting of rituximab is poorly understood, but may be due in part to the effects on KSHV-specific humoral immunity [36] [37] [38] [39] [40] . Also, rituximab alone may sometimes be inadequate in severe KSHV-MCD [41] [42] [43] . We combined rituximab with liposomal doxorubicin (R-Dox) with the rationale that liposomal doxorubicin would directly target CD20-negative KSHV-infected MCD plasmablasts and KS spindle cells, including those in lymph nodes that may provide paracrine stimulation for KSHV-MCD plasmablasts 44 . We describe a pilot study of R-Dox in HIV-infected KSHV-MCD patients with concurrent KS and/or inflammatory symptoms of at least moderate severity.
Patients and methods

Eligibility
Starting in 2004, patients with pathologically confirmed KSHV-MCD were enrolled in a natural history protocol (NCT00099073) with embedded prospective evaluations of several treatments. Patients were eligible for the study of R-Dox followed by consolidation therapy if they had at least one symptom and one laboratory abnormality attributed to KSHV-MCD. According to the protocol, RDox was preferred for patients with symptomatic KSHV-MCD and concurrent symptomatic KS, progression through virus-activated cytotoxic therapy, or disease severe enough to warrant immunochemotherapy, i.e. Eastern Cooperative Oncology Group (ECOG) performance status > grade 2 and/or at least one symptom or laboratory abnormality that would be considered
≥
Grade 3
For personal use only. and KSHV-MCD consolidation therapy was deferred.
KSHV viral load and serum viral IL-6
KSHV-viral copies per million peripheral blood mononuclear cells (PBMC)
were measured using polymerase chain reaction (PCR) 17, 45, 46 . KSHV DNA was assessed in DNA extracted from PBMC using K6 primers 45 . The number of cellular equivalents was determined using a human endogenous retrovirus 3 PCR assay 47 . Serum vIL-6 was measured using a sandwich enzyme linked immunosorbent assay 3,17 that does not cross-react with human IL-6 at concentrations up to 10,000 pg/mL 3, 17 . The lower limit of detection of vIL-6 was 1560 pg/mL.
Other assays.
Serum IL-6, IL-10 and other cytokines were evaluated using the MSD 96-Well Multiarray® Proinflammatory 7-plex Assay (Meso-Scale Discovery, 
Response evaluations
Patients were monitored day 1 of each cycle for clinical, biochemical, and radiographic responses using protocol-defined NCI KSHV-MCD criteria Table 1 ) to facilitate assessment of response and treatment decisions based on overall evaluation of eight indicator abnormalities (four symptom groups and four laboratory parameters) most closely associated with disease activity. This criteria was evaluated retrospectively.
The KSHV-MCD natural history protocol did not initially specify formal KS For personal use only. on July 10, 2017. by guest www.bloodjournal.org From assessments using modified ACTG criteria 48, 49 . While generally performed, they were not always done at time points related to R-Dox therapy. The protocol was amended in 2010 to specify timing of KS measurements. Where formal KS response assessments were not available at the end of R-Dox, physicianinvestigator reported KS status was noted from records of on-study clinical evaluations, and substantiated by formal assessment of measurements and photographs that were subsequently obtained during follow up.
Safety assessments
Safety was monitored each cycle and during post-therapy natural history evaluations. Evaluations included complete blood counts with differential, serum chemistries, urinalysis, CD4 counts, and HIV viral loads. AEs were graded using CTCAEv3.0.
Statistical considerations
Sample size was based on two-stage Simon optimal design, with α=0.15, β=0.15, aiming to rule out 5% and targeting a 25% clinical response rate. If 1 or more of the first 8 patients had at least a PR in one parameters (clinical, biochemical, or radiographic), a total of 14 patients were to be treated with RDox, with an option to treat more if 2 or more responded. Given the high response rate, 3 additional patients were treated for a total of 17. Event-free survival (EFS), defined as the time from starting R-Dox to time of KSHV-MCD progressive disease (PD), and overall survival (OS) were calculated using Kaplan-Meier methodology. Use of KS-specific therapy after completion of R-Dox 
Results
Patient characteristics
Between March 2006 and September 2010, 17 HIV-positive patients with symptomatic KSHV-MCD were administered R-Dox (Table 1) . Median CD4 count was 226 cells/μL (range 21 to 858); 7 patients had <200 cells/μL. All were on HAART; 14 for over one year, 3 patients newly started within 3 months of entry.
Twelve patients had a current or past history of KS (Table 1, Supplemental Table   2 ). Primary indication for selection of R-Dox included KSHV-MCD symptomatic through other therapy (8), concurrent KS requiring therapy (4), disease severe enough to warrant immunochemotherapy (5).
Most had been heavily pre-treated for KSHV-MCD and KS. 14 had prior therapy for KSHV-MCD: cyclophosphamide, doxorubicin, vincristine and 
KSHV-MCD responses
By NCI KSHV-MCD Response criteria, 15 patients (88%) had a clinical complete response (CR) after R-Dox and an additional patient had symptom-free disease, yielding 16 patients (94%) with a major clinical response (Table 2) . For personal use only. on July 10, 2017. by guest www.bloodjournal.org From remaining patient had PD and died with severe inflammatory disease manifestations, worsening KS and central pontine myelinolysis. PEL was found at autopsy. 13 patients (76%) had a biochemical CR and 2 patients had a biochemical partial response (PR), yielding 15 patients (88%) with a major biochemical response. Radiographically, 15 patients (88%) had a major radiographic response. 13 (76%) had normalization of lymphadenopathy (CR) and an additional 4 (24%) had greater than 50% decrease in adenopathy (PR) at the end of R-Dox. Likewise, 8 (47%) had complete resolution of splenomegaly and 7 (41%) had at least 50% relative decrease splenomegaly (PR). Overall, 5
(29%) had a CR by all criteria and an additional 9 (53%) had an overall PR, yielding 14 patients (82%) with a major response by all 3 criteria.
By KSHV-MCD Clinical Benefit Criteria, 14 (82%) patients obtained a CR by the end of R-Dox. One had a PR and 1 had stable disease (SD); these latter 2 subsequently obtained CR during consolidation therapy (94% CR by the end of therapy). One patient had PD.
KS outcomes
Ten patients had baseline KS: 6 had cutaneous KS (of whom 4 also had nodal KS) and 4 only nodal KS. All nodal KS was in biopsies that also showed KSHV-MCD. Two additional patients had a history of KS only. KS outcomes are summarized in Supplemental Table 2. In the 6 patients with cutaneous KS, after a median of 5 cycles (range 3-7) of R-Dox, KS outcomes compared to baseline were PR (2), SD (1) and documented clinical improvement (3). In the 3 patients The patient who developed cutaneous KS on R-Dox was lost to follow up. Table 3 lists 
Adverse events
Effect of R-Dox therapy on parameters associated with symptomatic KSHV-MCD, correlative immune biomarkers, and immune reconstitution
At the end of R-Dox, most parameters associated with symptomatic . Additional studies of serum FLC in KSHV-associated diseases are warranted.
In conclusion, this study provides evidence that R-Dox is generally well tolerated and has excellent activity in HIV-infected patients with symptomatic
For personal use only. on July 10, 2017. by guest www.bloodjournal.org From 22 KSHV-MCD. It is a particularly important option for patients with concurrent KSHV-MCD and KS. Only 2 patients had CD4+ counts less than 100 cells/μL, which is a risk factor for infectious morbidity associated with rituximab in patients with HIV-associated systemic lymphomas 66, 67 , and special precaution may be needed in this patient population. Future studies are required to assess the optimal duration of treatment for KSHV-MCD and the role of consolidation or maintenance therapy. Nonetheless, this study provides additional evidence that with appropriate therapy, durable remissions may be obtained in a majority of HIV-positive patients with KSHV-MCD.
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Gill Wilcoxon signed rank test). Log serum vIL-6 was less than the lower limit of detection (1560 pg/ml, or log 3.193) in 11 patients at baseline and 14 patients at the end of R-Dox. *Asterisk denotes a patient with progressive symptoms and rising KSHV viral load, serum hIL-6, serum IL-10, and serum vIL-6; he subsequently died and was diagnosed with PEL at autopsy.
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